Loading...
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Malpani, Rohit
Malpani, Rohit
Citations
Altmetric:
Titre
Publication date
2007-03-21
Document type
Briefing paper
Pages
37
Author(s)
Advisors
Editor(s)
Other Contributors
Affiliation
ePub Date
Submitted date
Local subject classification
MeSH
Country
Collections
Files
Loading...
English paper
Adobe PDF, 207.75 KB
Loading...
Arabic paper
Adobe PDF, 539.54 KB
Loading...
French paper
Adobe PDF, 242.07 KB
Loading...
Spanish paper
Adobe PDF, 248.44 KB
Description
The USA continues to impose TRIPS-plus rules on developing countries, thus preventing poor people from accessing inexpensive, generic medicines. Jordan was required under the terms of its WTO accession package and its free trade agreement (FTA) with the USA to introduce TRIPS-plus rules. Medicine prices have increased drastically, and TRIPS-plus rules were partly responsible for this increase. Furthermore, stricter levels of intellectual property protection have conferred few benefits with respect to foreign direct investment, domestic research and development, or accelerating introduction of new, effective medicines. Medicine prices will continue to rise in Jordan, but the country will be unable to use TRIPS safeguards to reduce their cost. Other developing countries implementing or considering FTAs with TRIPS-plus rules should consider the consequences for public health.
Language
English
Arabic
French
Spanish
Arabic
French
Spanish
Other Titles
Abstract
Citation
Publisher(s)
Journal
Journal Theme
Volume
Issue
Research Unit
DOI
Table of contents
Series
ISSN
EISSN
ISBN
978-1-84814-206-0